Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01796-6
Abstract: Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic… read more here.
Keywords: tremelimumab; solid tumors; durvalumab; plus tremelimumab ... See more keywords
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Sign Up to like & getrecommendations! Published in 2022 at "ESMO open"
DOI: 10.1016/j.esmoop.2022.100408
Abstract: BACKGROUND In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab plus… read more here.
Keywords: durvalumab; durvalumab plus; tremelimumab plus; plus tremelimumab ... See more keywords